Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Endometrial cancer
Trial Type:  Treatment
Results 1-25 of 52 for your search:
Start Over
Paclitaxel and Carboplatin with or without Metformin Hydrochloride in Treating Patients with Stage III, IV, or Recurrent Endometrial Cancer
Status: Temporarily closed
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GOG-0286B, NCI-2013-02284, NCT02065687
Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: Over 18
Trial IDs: ENGOT-EN2-DGCG/EORTC55102, NCI-2014-00983, 2010-023081-52, NCT01244789
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Status: Enrolling by invitation
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CO-338-014, NCI-2014-00430, NCT01968213
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ARN-AR18-CT-101, NCI-2016-00136, NCT02052128
Olaparib and mTOR Kinase Inhibitor AZD2014 or AKT Inhibitor AZD5363 in Treating Patients with Recurrent Endometrial, Triple Negative Breast, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0784, NCI-2014-01973, NCT02208375
Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INCB 54828-101, NCI-2015-00611, NCT02393248
A Phase 1/2a Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AL3818-US-001, NCI-2015-01926, NCT02558348
Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: E7080-A001-111, NCI-2016-00529, NCT02501096
Radiation Therapy with or without Cisplatin in Treating Patients with Recurrent Endometrial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: GOG-0238, NCI-2009-00603, CDR0000550975, NCT00492778
High Dose Rate Brachytherapy in Treating Patients with Endometrial, Cervical, Lung, Breast, or Prostate Cancer
Status: Active
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 18 to 90
Trial IDs: 09-C-0100, NCI-2013-01448, 090100, 302844, P08407, NCT00924027
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients with High-Risk Endometrial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 08-03-060, NCI-2013-01224, 07-062, NCI-2012-00458, NCT01041027
Carboplatin and Paclitaxel With or Without Trastuzumab in Treating Patients With HER2-Positive Stage III-IV or Recurrent Uterine Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 1012007786, NCI-2013-00894, NCT01367002
PI3K Inhibitor BKM120 in Treating Patients With Refractory Advanced Solid Tumors That Have PIK3CA Mutations
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-211, NCI-2012-00257, NCT01501604
Pathology Intraoperative Consultation in Tailoring Surgery in Patients With Endometrial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-GYN-130, NCI-2013-01938, NCT01512810
Everolimus, Letrozole, and Metformin Hydrochloride in Treating Patients with Advanced or Recurrent Endometrial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0543, NCI-2013-00960, RAD001CUS195T, NCT01797523
An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PUMA-NER-5201, NCI-2014-00495, 2013-002872-42, NCT01953926
Dasatinib in Treating Patients with Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GOG-0283, NCI-2014-00209, NCT02059265
Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: VX-EC-2-2013, NCI-2014-02177, NCT02064725
Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients with Stage IIIC-IV Uterine Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-02-058, NCI-2013-01226, NCT02112552
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GOG-3007, NCI-2015-00993, CRAD001CUS236T, NCT02228681
Levonorgestrel-Releasing Intrauterine System with or without Everolimus in Treating Patients with Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0944, NCI-2015-00919, NCT02397083
Start Over